恒瑞医疗 网址: www.hrmedical.com.cn

专业文献

载药微球动脉化疗栓塞术与常规动脉化疗栓塞术治疗胃癌特殊解剖部位肝转移的比较研究 -ag捕鱼平台

文字: 2020-8-14    浏览次数:294    


abstract

this study aimed to assess the relative safety and short-term efficacy of drug-eluting bead transarterial chemo­embolization (deb-tace) and conventional transarterial chemoembolization (c-tace) for treating peculiar ana­tomical sites of gastric cancer liver metastasis.

本研究旨在评价deb-tace(载药微球动脉化疗栓塞术)与c-tace(常规动脉化疗栓塞术)治疗胃癌特殊解剖部位肝转移的相对安全性和近期疗效。


of the 68 patients with gastric cancer liver metastases confirmed by imaging and pathology, 35 were treated with deb-tace and 33 with c-tace. the deb-tace group comprised 26 males and 9 females aged 28–75 years (56.8±6.3), and the c-tace group included 19 males and 14 females aged 33–77 (60.2±9.4) years. liver func­tions of the 2 groups were compared between pre-tace and 1-week and 1-month after tace. computed tomog­raphy and magnetic resonance imaging were reexamined at 1, 3, and 6 months after tace, and short-term ef­ficacy was assessed based on modified response evaluation criteria in solid tumors.

68例经影像学和病理证实的胃癌肝转移患者,其中35例采用deb-tace治疗、33例采用c-tace治疗。deb-tace组男性26人、女性9人,年龄28-75(56.8±6.3)岁;c-tace组男性19人、女性14人,年龄33-77(60.2±9.4)岁。比较两组患者术前、术后1周、术后1个月肝功能变化。在tace术后1个月、3个月、6个月复查ct和磁共振,并根据mrecist标准评估短期疗效。


one month following deb-tace and c-tace, the number of cases with objective response (or) was 29 cases (29 out of 35 cases, 82.9%) and 20 cases (20 out of 33 cases, 60.6%) and disease control (dc) in the 2 groups was 33 cases (33 out of 35 cases, 94.3%) and 26 cases (26 out of 33 cases, 78.8%) respectively (p=0.041, p=0.031). alanine transaminase (alt) and aspartate transaminase (ast) significantly increased in the deb-tace and c-tace groups 1 week later (p<0.001). there were no serious complications in the 2 groups; incidences of nausea and vomiting were significantly lower, but instances of fever were markedly elevated in the deb-tace group (p=0.023, p=0.016, respectively).

行deb-tace和c-tace术后1个月,or(客观反应)分别有29例(29/35例,82.9%)、20例(20/33例,60.6%)(p=0.041);dc(疾病控制)分别有33例(33/35例,94.3%)、26例(26/33例,78.8%)(p=0.031)。deb-tace组和c-tace组术后1周alt和ast显著升高(p<0.001)。两组无严重并发症;在deb-tace组,恶心和呕吐发生率显著降低(p=0.023),但发热发生率显著升高(p=0.016)。


the safety, feasibility, and short-term efficacy of deb-tace and c-tace in the treatment of gastric cancer liver metastasis are clear. deb-tace leads to less incidences of nausea and vomiting but more incidences of fever than c-tace.

deb-tace和c-tace治疗胃癌肝转移的安全性、可行性和近期疗效是明确的。deb-tace比c-tace更少出现恶心和呕吐,但发热发生率更高。


丨本文译者张健鑫

山东省肿瘤医院 介入二科

原文链接:https://mp.weixin.qq.com/s/u7m9_uc0sj1c-rnia9li5q